Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

Chemistry World March 7, 2007 Victoria Gill	The Brain's Insatiable Appetite Revealed It's no longer a question of will power. Scientists have shown how obesity disrupts the brain's ability to regulate appetite, meaning that the fatter a person becomes, the more difficult it is to resist those extra portions.
Psychology Today Mar/Apr 2008 Karen Wright	Consuming Passions Appetite may be the ultimate mind-body problem. Understanding the true nature of appetite is the only way to successfully obstruct it.
Chemistry World June 2011	Breaking through the barrier Getting drug molecules into the brain means crossing the defensive blood-brain barrier. Anthony King investigates how chemists are infiltrating the brain's fortress
AskMen.com July 7, 2014 Patrick Owen	Is It Impossible To Keep The Weight Off? The world is fatter than ever. In 2010 there were 1.5 billion people worldwide who were obese, and the trend is growing.
The Motley Fool February 8, 2011 Esterhuizen & Sellitti	Battle of the Bulge: Biotech Takes on Obesity and Diabetes Will recent advances in pharmaceutical research revolutionize the weight loss industry? It's still early days, but here are some of the stocks to watch.
Registered Rep. June 1, 2004 Bob Hirschfeld	The Virtue of Moderation With American obesity at epidemic proportions, diet products and weight-loss drugs are popular fare. However, many of the most promising obesity-control drugs await federal approval.
The Motley Fool June 25, 2010 Brian Orelli	Mark Your Calendars: Obesity Drugs Take Center Stage Orexigen Therapeutics has been given an FDA advisory committee meeting date, completing the dates for the trio of obesity drugs up for review.
The Motley Fool March 14, 2008 Brian Orelli	Weighing In on Obesity Drugs Could investing in drugmakers that produce weight-loss drugs help fatten your wallet?
The Motley Fool June 3, 2011 Brian Orelli	FDA Bullies Obesity Drugmakers It's been clear for some time that the Food and Drug Administration isn't particularly fond of obesity drugs. Now it's just being a bully.
The Motley Fool March 17, 2011 Brian Orelli	Taking a Bite Out of Amylin's Obesity Drug Potential Amylin Pharmaceuticals and Takeda announce they were putting a hold on the development of their obesity drug combination pramlintide/metreleptin due to safety issues.
The Motley Fool December 22, 2005 Karl Thiel	The Skinny on Obesity Drugs Drug companies are working on novel new ways to battle the bulge. Which pharmas' efforts might fatten your portfolio?
The Motley Fool January 31, 2011 Brian Orelli	5 Drugmakers Headed Back to the Drawing Board Sometimes an FDA rejection is more of a to-do list.
The Motley Fool June 30, 2010 Brian Orelli	When Researchers Attack, Investors Lose Drug investors have to watch out for a lot of things that can change their stock's price: earnings reports, clinical trial results, competitor's results, and FDA decisions.
Science News September 6, 2003 John Travis	A New Shot at Fighting Obesity Researchers who recognize the need for new obesity-fighting drugs are searching for such medicines among the complex web of biochemical signals that controls appetite. Two recent reports suggest that investigators are making progress in their quest but that its end is far from near.
Chemistry World July 18, 2011 Meera Senthilingam	Appetite for salt linked to drug addiction Researchers in the US and Australia have identified the mechanism underlying an ancient animal instinct: our appetite for sodium chloride (salt).
The Motley Fool May 27, 2011 Brian Orelli	Don't Believe the Obesity Hype Meta-analysis data isn't going to help Arena Pharmaceuticals' obesity drug.
The Motley Fool February 1, 2011 Brian Orelli	Orexigen Falls Short Its obesity drug fails in the final mile of the drug-development marathon.
Chemistry World June 28, 2012 Patrick Walter	FDA green lights new obesity drug Lorcaserin, which has been developed by US-based Arena Pharmaceuticals, in conjunction with Japan's Eisai, is the first obesity prescription medicine approved for 13 years.
The Motley Fool September 14, 2010 Luke Timmerman	Arena Obesity Drug Effective by "Slim Margin"; Shares Tumble The market is reacting negatively to news about the company's weight-loss drug.
The Motley Fool September 2, 2010 Luke Timmerman	Orexigen Nabs $1B Deal With Takeda to Market Obesity Drug, Shares Climb San Diego-based Orexigen Therapeutics has found a partner to help it compete in the growing market for drugs to combat obesity, Japan-based Takeda Pharmaceutical.
The Motley Fool July 13, 2010 Brian Orelli	A Triple Delight: 3 Stocks All Up More Than 10% What's good for the obese goose is good for the gander when it comes to new drug treatments for losing weight.
The Motley Fool December 22, 2010 Brian Orelli	Arena Charges On It seems Fool readers were a little more optimistic about the timing of Arena Pharmaceuticals' resubmission of its obesity drug to the Food and Drug Administration than the company is.
The Motley Fool September 8, 2010 Jim Mueller	3 Stocks to Play Biotech Three promising ideas for investing in this exciting area.
Chemistry World April 2008 Derek Lowe	Column: In the Pipeline The recent row over antidepressants reminds us how little we know about the brain.
American Family Physician July 15, 2000 Ethan M. Berke & Nancy E. Morden	Medical Management of Obesity Family physicians must treat any conditions associated with obesity while working with patients on methods to achieve and maintain weight loss...
The Motley Fool December 31, 2010 Brian Orelli	2010 FDA Approvals and a Look Ahead Recent history can help us handicap FDA decisions.
Chemistry World October 24, 2008 Matt Wilkinson	Europe suspends anti-obesity drug The European drugs watchdog, European Medicines Agency, has recommended that doctors stop prescribing Sanofi-aventis' anti-obesity drug rimonabant, because the risk of side effects is too high.
Chemistry World September 17, 2010 Andrew Turley	Obesity drugs strive for US approval Could 2010 yet be the year of the obesity drug? At first glance the signs are promising. Regulators in the US will soon decide whether to allow three new contenders onto this attractive market.
Chemistry World December 20, 2006 Richard Van Noorden	Blame it on the Bacteria The bacteria in human guts could be partially responsible for obesity, report US researchers.
The Motley Fool October 3, 2008 Brian Orelli	Merck Can't Fight the Munchies The pharma gives up on its anti-obesity drug.
The Motley Fool July 14, 2010 Luke Timmerman	Vivus Faces Turning Point Tomorrow Thursday's the big day. All eyes will be on Vivus and the FDA's decision on their new obesity drug
Chemistry World December 2006 Dennis Rouvray	Fat of the Land As we become progressively more rotund, our body chemistry undergoes critical changes that have a major impact on our health.
The Motley Fool March 2, 2011 Susmita Chatterjee	How to Capitalize on the Obesity Epidemic Does broader use of Allergan's Lap-Band signify competition for others?
HHMI Bulletin May 2012 Sarah C.P. Williams	Hungry for Pleasure, Hungry for Food Our drive to eat can be based on physical hunger or desire. The two aren't as separate as once thought.
Managed Care December 2004 Jack McCain	The Weight Debate, Continued This article presents the views of people who indulge in what many regard as health care heresy. They challenge the conventional wisdom that millions of Americans need to lose tons of weight, fast, to stave off diabetes, heart disease, cancer.
The Motley Fool July 16, 2010 Tom Hughes	Lessons Learned About the Outlook for New Obesity Drug Approval The recent FDA advisory committee meeting on Vivus' weight loss pill proved to us, once again, how incredibly difficult it is to successfully develop and register new drugs for obesity.
The Motley Fool May 21, 2010 Brian Orelli	And You Thought Biotech Was High-Risk, High-Reward Large clinical trials make cardiovascular drugs risky, but the rewards are there, too.
The Motley Fool November 7, 2008 Brian Orelli	Thinning Out the Pipeline The FDA says no to diet drugs from Sanofi-Aventis and Pfizer.
Chemistry World December 21, 2006 Tom Westgate	Molecular Probe Identifies Patients at Risk of Alzheimer's A new molecule could provide an early warning system for Alzheimer's disease, US researchers hope.
The Motley Fool March 29, 2010 Brian Orelli	Look for Companies That Strike First Head-to-head trials, whether they're run by companies or by third parties, can be scary. But the way to make big money is by selling drugs that offer superior benefits, so investors should welcome the onslaught of upcoming comparative trial data.
Psychology Today Jul/Aug 2008 Sora Song	Five Stealth Forces in Weight Loss Scientists are zeroing in on the unexpected ways molecular forces - including genes and viruses - impact your weight. In the process, they're upending the conventional wisdom on just what makes a successful diet.
AskMen.com Joshua Levine	Selling Your Body To Science Have you ever thought about the number of voluntary patients who basically sell their bodies to clinical trials in the name of science? Well, the number is staggering and it can reach well into the thousands. The main reason being the large paycheck that comes with the job.
Food Processing May 2011 Diane Toops	Toops' Scoops: Scientific Proof that Food Addictions Exist When it comes to food addictions, there may be no clear line between addictive and normal responses - adding to the evidence that all "addictions" act on the same motivational system in the brain.
Chemistry World July 18, 2012 Andrew Turley	Obesity drug approved in US US regulators have approved a new obesity treatment. Qsymia (phentermine, topiramate) tablets have been approved for overweight adults as part of a regimen that includes a low calorie diet and exercise.
Science News October 13, 2007 Janet Raloff	Food for Thought: Diminishing Obesity's Risks Mouse data suggest that, properly managed, obesity can be benign.
The Motley Fool February 16, 2010 Brian Orelli	For Blockbuster Cancer Drugs, Approvals Are the Easy Part Don't get too excited. As an investor, you can lower your risk by investing in cancer drug companies after a clinical trial success but before an FDA approval, but you'll also reduce your reward.
IEEE Spectrum March 2006 Samuel K. Moore	Psychiatry's Shocking New Tools Electronic implants and electromagnetic pulses are picking up where psychoactive drugs have failed.
The Motley Fool March 8, 2010 Brian Orelli	Really? A 59% Share Price Jump for That? Justified or not, InterMune skyrockets ahead of an FDA panel meeting.
The Motley Fool December 14, 2005 Stephen D. Simpson	Arena Fattens Wallets Positive phase 2 data sends the biotech's stock up big and raises hopes of a blockbuster.
Salon.com September 19, 2000 Tabitha M. Powledge	Germ theory of obesity gains weight An Indian researcher believes a virus may be responsible for obesity -- and he's not as crazy as he sounds.